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Abstract
Objective: Whether circulating microvesicles convey bioactive signals in neuro-
degenerative diseases remains currently unknown. In this study, we investigated
the biochemical composition and biological function of exosomes isolated from
sera of patients with Parkinson’s disease (PD). Methods: Proteomic analysis
was performed on microvesicle preparations from grouped samples of patients
with genetic and sporadic forms of PD, amyotrophic lateral sclerosis, and
healthy subjects. Nanoparticle-tracking analysis was used to assess the number
and size of exosomes between patient groups. To interrogate their biological
effect, microvesicles were added to primary rat cortical neurons subjected to
either nutrient deprivation or sodium arsenite. Results: Among 1033 proteins
identified, 23 exosome-associated proteins were differentially abundant in PD,
including the regulator of exosome biogenesis syntenin 1. These protein changes
were detected despite similar exosome numbers across groups suggesting that
they may reflect exosome subpopulations with distinct functions. Accordingly,
we showed in models of neuronal stress that Parkinson’s-derived microvesicles
have a protective effect. Interpretation: Collectively, these data suggest for the
first time that immunophenotyping of circulating exosome subpopulations in
PD may lead to a better understanding of the systemic response to neurodegen-
eration and the development of novel therapeutics.
Introduction
Parkinson’s disease (PD) is an age-related, neurodegenerative
disease, characterized primarily by a movement disorder and
pathologically by intraneuronal accumulation and misfold-
ing of a-synuclein.1 It is now well established that clinical
and pathological changes are also seen peripherally such as in
the gut, and may predate central neurodegeneration.2 Simi-
larly, molecular adaptations have been described in the blood
of patients with PD3,4 but the significance of such nonneuro-
nal changes for the disease process remains unclear.
Circulating microvesicles are membrane-bound nanopar-
ticles that are released in biofluids by most cell types and
depending on their cargo and site of origin, are regulated by
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distinct intracellular stimuli. Exosomes are 40–150 nm
vesicles derived from the invagination of the limiting
membrane of late endosomes, whereas ectosomes are
100–1000 nm in size and originate from the plasma mem-
brane.5 Because of this mode of generation, microvesicles
may reflect intracellular changes that occur in response to a
pathological condition or represent a form of paracrine
interaction between healthy and disease tissues. Such inter-
actions have been extensively documented in cancer,6
including brain tumors,7 where microvesicles may convey
either antineoplastic or trophic support to the invading
malignant cells. Given that PD has widespread extracranial
manifestations, we asked whether circulating microvesicles
derived from patients’ sera exhibit distinct biochemical com-
position and function.
Materials and Methods
Patient samples
Serum samples were obtained from PD patients and age-
matched controls that were enrolled in the Oxford PD
Cohort. PD patients diagnosed within the previous
3.5 years were prospectively recruited over 2 years (ethics
study 10/H0505/71). For proteomic analysis, the control
subjects consisted of three groups of 12 subjects each (aver-
age age 64 years; 18 males; 18 females); the sporadic PD
group consisted of three groups of 12 subjects each (average
age 64 years; 17 males; 19 females); the glucocerebrosidase
(GBA) heterozygous subjects consisted of one group of 13
patients (average age 62 years; seven males; six females). As
a disease-control group, patients with amyotrophic lateral
sclerosis (ALS) were obtained from the Oxford Study for
Biomarkers in Motor Neuron Disease (“BioMOx”, ethics
study 08/H0605/85). Serum was used from 22 individual
patients (average age 65 years; 14 males; eight females). For
the validation phase of the study, serum from 90 different
subjects was used as follows: controls consisted of three
groups of 10 subjects each (average age 68 years; nine
males; 21 females). PD consisted of six groups of 10 sub-
jects each: three groups comprised PD patients at Hoehn &
Yahr stage 1 (average age 64 years; 20 males; 10 females)
and three groups consisting of PD patients at Hoehn &
Yahr stage 2 (average age 67 years; 18 males; 12 females).
For proteomics, 0.6 mL of serum was pooled from each
individual in each group. For cell-based assays, 1 mL of
serum was individually extracted from 30 patients and 30
age-matched controls.
Microvesicle isolation from serum
Serum samples were subjected to serial centrifugation
with all steps performed at 4°C: initially at 800g for
10 min followed by 1500g for 10 min and lastly 17,000g
for 15 min. The resultant supernatant was filtered
(0.2 lm filter) and spun at 160,000 g for 1 h. The pellet
from each group was resuspended in 5 mL of Hanks
Balanced Salt Solution (HBSS) and spun in an ultracen-
trifuge at 160,000 g for 1 h at 4°C. The final pellet
containing washed microvesicles was resuspended in
HBSS for subsequent analysis.
Nanoparticle-tracking analysis
Microvesicle size and concentration were assessed using a
NS500 instrument (Nanosight Ltd., Amesbury, UK)
equipped with a 405-nm laser and a CMOS camera as
described previously.8
Mass spectrometry
Samples were processed by nano-UPLC-MS/MS using a
Thermo LTQ Orbitrap Velos mass spectrometer coupled
to a Waters nanoAcquity UPLC system as described pre-
viously9 with some modifications. In brief, proteins were
precipitated using chloroform/methanol followed by
trypsin digestion, desalting using C18 SepPac cartridges
(Waters, Milford, MA, USA) and resuspended in water
with 0.1% Trifluoroacetic acid, 2% Acetonitrile. Samples
were subsequently analyzed by nanoUPLC-MS/MS using
a Waters, nanoAcquity column, 75 lm 9 250 mm,
1.7 lm particle size, and a gradient of 1–40% acetoni-
trile in 60 min at a flow rate of 250 nL/min. Mass spec-
trometry analysis was performed on a Thermo LTQ
Orbitrap Velos (60,000 Resolution, Top 20, CID, Wal-
tham, MA, USA). Proteins were identified using PEAKS
(http://www.bioinfor.com/peaks) by applying a false dis-
covery rate (FDR) of 1% and quantified with LC Pro-
genesis softwarev v4.1 (Nonlinear Dynamics, Newcastle,
UK). Principal component analysis (PCA) plots were
generated using XLSTAT (Addinsoft Inc., New York,
USA) & Microsoft Excel (Microsoft, Redmond, WA,
USA). Gene Ontology term enrichment analysis was
conducted with AmiGO2/Panther using the 10 most
enriched GO terms (P-value) in the list of identified
proteins from each sample.
Immunoblotting
Samples were run on NuPAGE 10–12% Bis-Tris gels (Life
Technologies, Paisley, UK). The following primary anti-
bodies were used: rabbit anti-flotillin (1:1000 Abcam, Cam-
bridge, UK), rabbit anti-Tsg101 (Abcam 1:250), rabbit
anti-syntenin 1 (Abcam, 1:1000). Blots were visualized
using HRP-conjugated secondary antibodies and the ECL
Detection Reagent (GE Healthcare, Little Chalfont, UK).
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Preparation and treatment of cortical neurons
All experiments were conducted in accordance with insti-
tutional and governmental guidelines. Primary cortical
neurons were prepared from P0 rats. Cortical neurons
(1.5 9 105 cells/24-well or 4 9 104/96-well) were
cultured for 7 days in neurobasal/B27 medium at 37°C.
Half of the medium was replaced every 3 days and mito-
tic inhibitor (2 lmol/L cytosine b-D-arabinofuranoside
[araC], Sigma (St Louis, MO, USA) was added during the
first media exchange to arrest glial growth. For nutrient
deprivation (ND), neurons were cultured for 5 h in med-
ium lacking B27 supplement before exposed to microvesi-
cles or liposomes. Natural or synthetic vesicles were
applied to ND medium and incubated for further 16 h.
The number of microvesicles and liposomes was deter-
mined by nanoparticle-tracking analysis (NTA) analysis
and equal numbers of vesicles were added (800 vesicles/
neuron, 24-well; 80 vesicles/neuron, 96-well) as per previ-
ously published protocols.10 Liposomes (Sigma) were pre-
pared by rotatory evaporation and resuspended in HBSS.
For sodium arsenite experiments, neurons were cultured
in neurobasal/B27 medium. Neurons preincubated with
microvesicles were treated with 0.5 mmol/L arsenite for
1 h at 37°C.
Immunofluorescence staining of cortical
neurons
Cortical neurons were plated, fixed, and stained with
mouse anti-b-III tubulin (1:1000, BioLegend, Dedham,
MA, USA), rabbit anti-cleaved caspase 3 (1:400, Cell-
Signaling Technology, Danvers, MA, USA), and rabbit
anti-syntenin 1 (Abcam, 1:2000). Goat anti-mouse Alexa-
Fluor488 and goat anti-rabbit AlexaFluor568 (both Invi-
trogen, 1:500) were used as secondary antibodies and cells
were imaged with a fluorescent (DM2500, Leica, Solms,
Germany) or confocal (LMS710, Zeiss, Oberkochen, Ger-
many) microscope. For quantification of caspase three
positive neurons, digital photographs of five random
fields were taken (Rotera XR Fast 1394; QImaging, Sur-
rey, UK) and the percentage of caspase three positive,
b-III tubulin-positive neurons were counted in an unbi-
ased manner. All experiments were repeated three times
and presented data were based on a total count of at least
2500 neurons per condition per experiment.
Microvesicle uptake studies
Purified patient microvesicles were labeled with the fluo-
rescent marker PKH67 (Sigma) for 3 min at 37°C fol-
lowed by ultracentrifugation at 160,000g for 1 h. Labeled
microvesicles were washed once and immediately added
to neurons for 4–12 h. Uptake was visualized by confocal
microscopy.
Neuronal viability assays
Neuronal viability was assayed by MTT assay: 0.5 mg/mL
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
(MTT, Sigma) was dissolved in ND medium and added to
cortical neurons for 2 h. Formazan crystals were solubilized
in Dimethyl sulfoxide and absorbance was measured at
570 nm using a plate reader (FLUOstar Optima; BMG
Labtech, Ortenberg, Germany).
Statistical analysis
Raw protein abundance values were first normalized to
total protein content. Label-free relative protein quantita-
tion was conducted with Progenesis LCMS v4.1 (nonlin-
ear Dynamics) on proteins identified with at least two
unique peptides using one-way analysis of variance, P
value <0.05. Microvesicle-treated neurons were compared
between patients and healthy controls using t-test. Only P
values < 0.05 were considered statistically significant and
are indicated by asterisks. Error bars represent the stan-
dard error of the mean.
Results
We successfully adapted previously validated protocols
based on filtration and differential centrifugation,11 to
isolate circulating microvesicles from human serum. As
shown in Figure 1A, our protocol effectively minimized
contamination with highly abundant serum proteins, thus
overcoming a major challenge in the analysis of complex
proteomes. We used NTA to quantitate the number of
purified microvesicles and found that the mean size of
the most abundant vesicles (about 120 nm) corresponded
to exosomes. This conclusion was supported by the detec-
tion of the common exosomal markers Tsg101 and flotil-
lin by immunoblotting and electron microscopy showing
that the isolated microvesicles are membrane bound
(Fig. 1B–D). As a positive control, we spiked the serum
with purified exosomes from conditioned media derived
from NSC34 cells. We observed an increment in the
corresponding vesicle size and abundance indicative of
exosomes as well as an increase in relevant protein
markers (Fig. 1B and C).
We then asked whether the proteomic profile of cir-
culating microvesicles differed in PD compared to con-
trols. In pilot experiments, we determined that at least
7 mL of a starting volume of serum was needed for
adequate protein detection in the final microvesicle
preparation. Since this volume is not easily accessible in
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Figure 1. Isolation and characterization of circulating microvesicles. (A) Flow diagram showing the extraction method used and Coomassie
staining of the final microvesicle preparation. Note that an additional wash step significantly reduces the number of contaminant proteins without
major changes in microvesicle numbers. (B) Nanoparticle-tracking analysis of serum microvesicles revealed a major peak at the size corresponding
to exosomes isolated from NSC34-conditioned media, whereas spike-in experiments showed a further increment in microvesicles of the same size.
(C) Immunoblotting confirmed the presence of the exosome markers flotillin1 and Tsg101 both in cell-conditioned media and serum preparations
(D) Electron microscopy showed membrane-bound microvesicles, negatively stained with 2% aqueous uranyl acetate on a formvar film. (E) Venn
diagram showing protein overlap between albumin/immunoglobulin depleted serum, serum microvesicles, and human cell lysates. Proteins were
quantified using Oribtrap-Velos LC-MS/MS. The enrichment for serum-derived microvesicles enables the identification and quantitation of proteins
that are not detected in routinely processed serum samples as shown by gene ontology analysis.
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large cohorts of patients, we performed this initial study
on grouped serum samples as detailed in the Methods sec-
tion. One advantage of this approach, which has been used
widely in serum and plasma proteomic studies, especially
investigations of disease mechanisms12 is that it may mini-
mize biological variation, making it more likely to detect
robust biochemical trends that are relevant to the disease
process. To assess the sensitivity of our mass spectrometric
analysis (Orbitrap LC-MS/MS) on these preparations, we
first compared the abundance of proteins identified in
grouped sera of the same 12 healthy volunteers when
extracted by either a standard albumin/immunoglobulin
depletion method13 or using our isolation protocol. We
found that our method of microvesicle isolation identified a
group of proteins that were not detected among the most
abundant proteins in routinely processed sera (Venn dia-
gram, Fig. 1E). In addition, gene ontology term enrichment
analysis confirmed that exosome preparations had a distinct
profile with 40% of identified proteins being vesicle-associ-
ated (Fig. 1E). Thus, pooled sera could be used to identify
unique biochemical trends that are enriched in circulating
microvesicles from disease and healthy-controlled condi-
tions.
We then performed the same mass spectrometric
analysis on grouped patient samples. We used three bio-
logical replicates for sporadic PD-, age-, and comorbidi-
ty-matched controls and one group of patients with
ALS, an unrelated neurodegenerative disease. Because PD
is heterogeneous, we also considered whether changes
that are detected in sporadic disease were also seen in
patients with heterozygous mutations in GBA, which
causes PD that is clinically and pathologically indistin-
guishable from sporadic cases. Protein identification was
based on unique peptides identified in two technical
replications. Using this cutoff, we detected 1033 (Table
S1) proteins across all patient groups with a FDR of less
than 1%. Label-free relative protein quantitation was
conducted with Progenesis LCMS v4.1 (nonlinear
Dynamics) on proteins identified with at least two
unique peptides. Eighty-two proteins were differentially
abundant between control and PD groups (Fig. 2A and
Table S2). It is noteworthy that the four PD groups
including the one with GBA mutations (blue dots repre-
senting the average vectorial position of all proteins in
each sample, Fig. 2A) clustered distinctly from control
or ALS samples. These data suggest that GBA-positive
and sporadic PD samples contain similar microvesicle-
associated protein changes. Based on these data, we
found that 54 of the 82 proteins further differentiated
PD from ALS-derived microvesicles (Fig. 2B, and Tables
S3, S4) with 23 of these 54 proteins previously shown to
be constituents of exosomes (ExoCarta dataset).14 Nota-
bly, we did not detect enrichment for disease-associated
proteins such as a-synuclein or tau in these prepara-
tions. To confirm the result of our proteomic analysis,
we then tested by immunoblotting the abundance of
one of these exosomal markers, syntenin 1, in samples
prepared from a different set of grouped patient samples
(total 90 different subjects divided into groups of 10).
We found that syntenin 1 was elevated in cases of early
PD (Hoehn and Yahr 1 and 2) compared to control sera
when corrected for either total vesicle number or the ex-
osomal protein flotillin (Fig. 2C). Collectively, our prote-
omic profiling indicates that circulating exosomal
cargoes within the microvesicle preparations are differen-
tially regulated in neurodegenerative diseases.
Syntenin 1 is an important regulator of exosome bio-
genesis.15 Its enrichment in PD-derived samples
prompted us to investigate whether the abundance of
exosomes is increased in PD using NTA in individually
extracted patient samples. These data showed that there
is no significant difference in the number or mode size
of microvesicles between PD patients and healthy con-
trols (Fig. 3). It is thus possible that enrichment of spe-
cific proteins in PD-derived exosomes may reflect
subpopulations with distinct biological properties. To
investigate this hypothesis, we examined the effect of
microvesicles extracted from individual patients on pri-
mary rat cortical neurons subjected to ND, which was
previously shown to induce both exosome uptake and
oxidative stress.10 The identification of syntenin 1
enabled us to study whether primary rat cortical neurons
internalize human exosomes. To this end, we used
human-specific antibodies and observed syntenin 1-posi-
tive vesicles in neurons treated with patient-derived
microvesicles (Fig. 4A) but not liposomes or untreated
controls (not shown). Using microvesicles prelabeled
with the fluorescent dye PKH67, we confirmed that
these vesicles are internalized rather than fused with the
plasma membrane (Fig. 4A). We then compared the
effect of PD-derived microvesicles to healthy controls.
We first stained and quantified in an unbiased fashion
microvesicle-treated b-III tubulin-positive neurons for
caspase 3 activation, which is an indicator of apoptosis.
Strikingly, we found that neurons treated with PD-
derived microvesicles had significantly less activated cas-
pase 3-positive neurons compared to those treated with
control microvesicles (Fig. 4B). To corroborate these
findings using an alternative readout of toxicity, we used
the MTT assay in either nutrient deprived or sodium
arsenite treated neurons that were preincubated with
microvesicles. We found that the metabolic activity of
neurons treated with PD-derived microvesicles was sig-
nificantly improved under both conditions when com-
pared to ones derived from age-matched controls
(Fig. 4C).
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Discussion
Our data provide novel insights into the disease-specific
systemic response that is induced in neurodegenerative
disorders. The discovery of distinct protein changes in
the absence of significant differences in microvesicle
numbers or size suggests that in PD there is a subpopu-
lation of vesicles that is either differentially regulated or
enriched for certain proteins in response to the disease
process. Evidence from proteomics, imaging and nano-
particle-tracking analysis indicate that the majority of
these microvesicles have properties that are typical of
exosomes. It is therefore likely that disease-relevant exo-
somes are detected in the circulation and serve-specific
functions. This conclusion is also supported by the dif-
ferential effect of PD-derived exosomes using our viabil-
ity readouts in neuronal cultures. Although these
neuronal assays are not disease models, they raise for
the first time the intriguing possibility that there is an
innate systemic response to neurodegeneration that may
be protective. Whether this is tissue-specific or general-
ized remains currently unknown, but evidence suggests
that peripherally injected exosomes can cross the blood–
brain barrier in mice to exert intraneuronal effects.16 On
the other hand, exosomes have been proposed as effec-
tors of the prion-like propagation of misfolded
proteins.17 Contrary to a previous report that a-synuc-
lein is increased in plasma microvesicles from PD
patients,18 our unbiased grouped analysis did not detect
enrichment of a-synuclein in PD-derived serum micro-
vesicles or a detrimental effect when taken up by neu-
rons. It is possible that such discrepancies may reflect
technical differences in microvesicle isolation but given
that a-synuclein is abundant in the circulation and
Figure 2. Differential proteomic composition of PD-derived microvesicles. (A) Significant protein differences were calculated after grouping of the
samples into controls and PD (ANOVA P < 0.05). Principal component analysis (PCA) shows the separation of the analyzed samples (blue dots)
and the loading of the 82 proteins (red dots). Syntenin 1 is marked with * (1.8-fold increase, P < 0.009). (B) Fifty-three proteins of the 82
proteins in (A) further separate PD from ALS samples (ANOVA P < 0.05). (C) Immunoblotting with specific antibodies against syntenin 1
confirmed the mass spectrometry finding in a separate group of early PD patients (Hoehn & Yahr 1 or 2) compared to controls (*P < 0.02, t-test).
PD, Parkinson’s disease; ANOVA, analysis of variance; ALS, amyotrophic lateral sclerosis.
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known to easily associate with membranes, caution is
required when interpreting candidate-based measure-
ments. Accordingly, a-synuclein was not detected in a
proteomic analysis of pooled CSF exosomes.19 It is
important to note that our data do not exclude the
possibility that a-synuclein is secreted in exosomes in
the neuronal microenvironment under pathological
conditions.
Despite the unique protein changes in PD-derived
microvesicles reported herein, the specific mediators of
their biological functions and regulators of their release
remain unclear. Our identification of proteins with chap-
erone or anti-oxidant properties (Table S3) suggests two
potential protective effectors. Exosomes are also a rich
source of RNA,20 which could contribute to the observed
or additional effects. In addition, syntenin 1 which is
implicated in the biogenesis of exosomes15 was shown to
act as an intracellular adaptor for diverse signaling path-
ways.21 An alternative explanation for our cellular obser-
vations is the differential expression of proteins in
exosomes that promote specifically their neuronal uptake
rather than their intracellular effect. Exosome prepara-
tions from cell lines have different cell-binding specifici-
ties when incubated with primary neurons22 and various
membrane-bound proteins have been implicated in exos-
omal uptake.23 In our PD preparations, we found an
enrichment in Integrin b1, whereas the common exoso-
mal tetraspanins were equally detected in all groups.
These data suggest a potential role for Integrin b1 in such
a neuron-specific exosome binding or uptake mechanism.
It is now critical to clarify these outstanding questions. In
this respect, our proteomic analysis could provide useful
markers for in-depth profiling of specific exosome
subpopulations.
Although this study was not designed to identify
biomarkers, our data suggest that immunophenotyping
of circulating exosomes may hold promise for the
development of tractable disease markers in neurode-
generative diseases. Importantly, further characterization
of the biogenesis of selective exosome subpopulations
may provide new insights into the systemic self-defense
mechanisms that are activated during Parkinson’s path-
ogenesis.
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Figure 3. Microvesicle abundance and size do not differ between PD
patients and controls. NTA was performed on microvesicles extracted
from individual PD patient samples and healthy-matched controls
(n = 20 per group). The NTA profiles showed a single peak that is
typical of exosomes (100–120 nm) as demonstrated by the close mode
size clustering of microvesicles from each sample (A). When averaged,
the mean size (panel A) or concentration (B) of exosomes was not
significantly different between the two groups. Error bars indicate
standard deviation. PD, Parkinson’s disease; NTA, nanoparticle-tracking
analysis.
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Figure 4. Parkinson’s disease (PD)-derived microvesicles convey a neuroprotective effect. (A) Confocal images of human-specific anti-syntenin 1
(red) and 4‘,6-diamidino-2-phenylindole (nucleus, blue) staining showing uptake of human microvesicles in primary rat cortical neurons. Neuronal
uptake was confirmed using exosomes prelabeled with the PHK67 fluorescent dye. (B) Caspase 3 activation was significantly reduced in neurons
treated with PD-derived microvesicles compared to controls (n = 20 per group, P < 0.05). Representative images of caspase 3 and b-III tubulin
doubly positive neurons under different experimental conditions. (C) Neuronal metabolic activity was assessed by the MTT assay in neurons
pretreated with PD or control exosomes under conditions of either nutrient deprivation (left graph, n = 30 per group, P < 0.05) or treatment with
0.5 mmol/L of sodium arsenite (right graph, n = 20 per group, P < 0.05).
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. List of the 1033 proteins that were identified
across samples.
Table S2. List of proteins that were significantly up- or
downregulated in PD-derived microvesicles compared to
age-matched healthy controls.
Table S3. List of proteins that were differentially regu-
lated in PD-derived microvesicles compared to those with
ALS. Those previously associated with exosomes are
shown in bold.
Table S4. List of proteins that were differentially
regulated in ALS-derived microvesicles compared to
controls.
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